Myriad Genetics launches Prolaris + AI prostate cancer test combining genomics, digital pathology AI

• Myriad Genetics will launch the Prolaris + AI prostate cancer test at the end of May, combining genomics with AI-based digital pathology.
• Clinical validation results were already disclosed in a recent study, with an accompanying preprint posted.
• The study supports the AI score as an independent indicator of near-term biopsy upgrading risk in men eligible for active surveillance.
• The test aims to sharpen active-surveillance selection, guide surveillance intensity, reduce unnecessary treatment, support single-modality treatment decisions.
• The AI metric will be added to US Prolaris Biopsy Tests processed from May 29, excluding New York State pending expected clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605261605PRIMZONEFULLFEED9726580) on May 26, 2026, and is solely responsible for the information contained therein.